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1370ABSTRACT
Background. In simultaneous pancreas-kidney transplantation (SPKT), persistence or
recurrence of pancreatic autoantibodies (PAs) has been associated with pancreas graft
(PG) autoimmune-driven injury. Our aim was to analyze the impact of PAs on PG survival.
Methods. Between January 1, 2000, and December 31, 2017, we studied 139 patients with
post-SPKT antieglutamic acid decarboxylase (GAD) autoantibody. Alloimmune (ALI)
events were defined as PG rejection and/or de novo donor-specific antibodies (DSA).
Hence, 3 groups were defined: patients without ALI events or anti-GAD (n ¼ 42), those
with ALI events (n ¼ 14), or those only with autoimmune events (positive for anti-GAD
and no ALI events; n ¼ 83).
Results. Male sex was predominant (n¼ 72, 52%). Median age was 35 years (interquartile
range: 31-39) and median follow-up was 6-7 years (interquartile range: 4.1-9.2). Regarding
anti-GAD positivity post-SPKT (n ¼ 90, 65%), no differences were observed concerning
age, sex, anti-HLA antibodies, HLA mismatch number and de novo DSA. ALI events were
present in 10% (n ¼ 14). PG survival 15 years post-SPKT was better in patients without
immune events (96%) followed by those with ALI (69%) and autoimmune events (63%)
(P ¼ .025). Anti-GAD was associated to higher annualized mean Hb1AC (P ¼ .006) and
lower mean C-peptide (P ¼ .013). According to pre- and post-SPKT anti-GAD status,
conversion from negative to positive was associated to worse (63%) 10-year PG survival
(P ¼ .044), compared to persistence of negative (100%) or positive anti-GAD (88%).
Anti-islet cell and anti-insulin autoantibodies had no impact.
Conclusion. Anti-GAD presence post-SPKT was associated to higher pancreas
disfunction and lower PG survival. De novo anti-GAD seems to offer a particular risk of
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þ351291705600. E-mail: nicole.pest@gmail.comGROWING evidence in the last 2 decades has beenconsolidating the concept that insulin-dependent
diabetes mellitus (IDDM) is a chronic, destructive
organ-specific autoimmune (AI) disorder. Sutherland et al
[1] documented IDDM recurrence in pancreas transplant
back in 1984. The first described cases were from HLA
identical brothers with minimal immunosuppression [2].
These observations led to the hypothesis that recurrence of
disease (AI isletitis leading to diabetes) was a major
histocompatibility complex-restricted phenomenon.0
rg/10.1016/j.transproceed.2020.02.035Consecutive studies demonstrated that AI recurrence can
occur independently of HLA match [3] and regardless of
adequate immunosuppression [4]. Nevertheless, improved
immunosuppression decreased the incidence of immuno-
logic failures of whole pancreas grafts (PGs), a processª 2020 Elsevier Inc. All rights reserved.
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AUTOANTIBODIES IN PANCREAS GRAFT SURVIVAL 1371usually categorized as chronic rejection. Growing evidence
indicates that chronic islet autoimmunity may eventually
lead to recurrent diabetes and PG failure. It is reported
that recurrent IDDM explains 50% of the immunologic
failures, while the other 50% is attributed to chronic graft
rejection [5].
IDDM recurrence is caused by the presence of inflam-
matory T-cell infiltrate targeting beta cells (insulitis) and
sparing exocrine tissue, with no evidence of acute or chronic
graft rejection. The presence of pancreatic autoantibodies
(PAs), anti-islet cell (ICA), antieglutamic acid decarbox-
ylase (GAD), anti-insulin autoantibodies (IAA),
anti-tyrosine phosphatase (IA2) and anti-tyrosine phos-
phatase (anti-ZnT8) is currently used as a noninvasive
screening tool for follow-up (FU) of pancreas transplant,
assuming that recurrence or rise of these autoantibodies
titers are potential indicators of IDDM recurrence. It is
unknown if these antibodies have a pathogenic action per se
or are simply the result of a pancreatic lesion [6]. Never-
theless, there is undoubtedly an association between the
presence of PAs and pancreas beta cells dysfunction after
SKPT [7,8], being the majority of these antibodies detected
in patients with biopsy specimens confirming AI recurrence.
Positive PAs after simultaneous pancreas-kidney trans-
plantation (SPKT) may never occur or it may be intermit-
tent or persistent. Unfortunately, the real influence of PAs
in PG dysfunction and survival is still controversial. Some
authors have observed the association between recurrence
of PA and poor pancreas survival [9,10], while others did
not find a relationship [11,12].
This study provides a thorough analysis of the PAs and
their impact on recurrent autoimmunity and PG survival.METHODS
All 211 consecutive adult patients who received a SPKT between
January 2000 and December 2017 with more than 6 months of FU
were investigated. All SPKT were performed at Renal and
Pancreatic Units of Centro Hospitalar Universitário Porto,
Portugal. Patients received induction therapy using a polyclonal
antithymocyte globulin, 3 mg/kg for 5 to 7 days, and had similar
triple maintenance immunosuppression, consisting of oral tacroli-
mus, mycophenolate mofetil and prednisolone. Moreover, cyto-
megalovirus prophylaxis was always performed for at least 6 months
with oral valganciclovir. In terms of surgical technique, pancreas
transplants were performed using a systemic-enteric drainage.
At initial evaluation, 72 patients were excluded as they had no
consistent anti-GAD assessment post-SPKT. Hence, the final study
cohort comprised the remaining 139 SPKT patients. All patients
were followed from time of transplant until death or graft failure
until December 31, 2018. Death-censored PG survival was deter-
mined from the time of SPKT until pancreas failure, patient death,
or end of FU.
Blood samples were systematically collected to prospectively
measure PAs. Screening was performed during the pretransplant
evaluation; on admission day or in the early days thereafter; after
transplantation at 6 months, 12 months; and then once per year
after SPKT. During FU, a median of 4 screening samples (range, 2-
6) per patient were performed. Anti-GAD were measured using theradio-ligand assay CentAK anti-GAD65 (MEDIPAN GMBH,
Berlin, Germany). ICA were determined by enzyme-linked immu-
nosorbent assay test, using the Isletest-ICA (BIOMERICA, Irvine,
CA, United States). IAA were measured using the radioimmuno-
assay RiaRSRIAA (RSR Limited, Cardiff, United Kingdom). Pa-
tients were considered positive for PA when anti-GAD antibodies
were >1.45 U/mL, ICA >1.05, and IAA >0.4 U/mL. The normal
range for glycated hemoglobin (HbA1c) was 3.8% to 5.6% (18-38
mmol/mol) and for C-peptide 1.1 ng/mL to 4.4 ng/mL. Continuous
data were described using mean and standard deviation (SD) or
median and interquartile range (IQR), and categorical data were
expressed as number (and percentages). Categorical data including
demographic, clinical, and immunologic features were compared
using Pearson c2 test or the Fisher exact test, as appropriate.
Continuous variables were compared with Student t test or Mann-
Whitney U test, as appropriate. Annualized mean HbA1c and C-
peptide values were assessed by univariate linear mixed regression
model that imputed subject-specific random effects (no intercept
and slope time in years) on an unstructured covariance matrix. The
dependent variable was all HbA1c and C-peptide measurements,
and the independent variable (anti-GAD post-SPKT status) was
entered as 2-way interaction term between them and the time (in
years) variable. Graft survival curves were done using Kaplan-Meier
method and compared by log-rank test. A two-sided P value < .05
was considered as statistically significant. Statistical calculations
were performed using STATA/MP, version 15.1 (Stata Corp, Col-
lege Station, TX, United States).RESULTS
Study Population
Studied population median FU was 6 to 7 years (4.1-9.2).
The incidence of rejection and/or de novo donor-specific
antibody (DSA) was 10% (n ¼ 14). Seven patients died.
PG loss occurred in 16 patients.
Autoimmunity: Prospective Analysis of Pancreatic Antibodies
Of the 139 SPKT patients, 19% were positive for anti-GAD
antibodies before transplantation; 11% were ICA-positive;
and 24% were IAA-positive. IAA (P ¼ .470) and ICA
(P ¼ .945) did not reach significant difference concerning
PG survival. Anti-GAD was the only antibody that showed
impact on PG outcomes (P ¼ .001). Consequently, the pa-
tients were separated into 2 groups based on the presence
(n ¼ 90) or absence (n ¼ 49) of anti-GAD after SPKT.
Comparison of baseline characteristics of global cohort and
according to anti-GAD status post-SPKT is presented in
Table 1.
Anti-GAD first detection timing ranged from 1 to 3 years
post SPKT (median 1 year). Most anti-GADþ (n ¼ 47,
52%) were detectable in the first year of FU screening.
Anti-GAD antibodies were detected post-transplant in 90
(65%) patients. There were no significant differences be-
tween the 2 groups concerning donor/receptor age, IDDM,
length of stay, presence of de novo DSA, number of anti-
HLA, and type/number of mismatches. A trend toward a
lower body mass index (P ¼ .046) in anti-GADþ patients
was also noticeable. Comparison of annualized mean
HbA1c and C-peptide levels according to anti-GAD
Table 1. Baseline Characteristics According to Recipient, Transplant, and Donor
Total (N ¼ 139)* Anti-GADþ (n ¼ 49) Anti-GAD-(n ¼ 90) P Value
Baseline
Recipient
Age, y, median (IQR) 35 (31-39) 35 (31-41) 35 (31-39) .465
Female sex, n (%) 67 (48) 24 (49) 43 (48) .892
Years of IDDM, median (IQR) 24 (20-28) 24 (20-30) 23 (20-27) .199
Days of stay, median (IQR) 15 (12-24) 16 (12-22) 15 (12-24) .730
BMI, median (IQR) 21.9 (20.5-23.7) 22.6 (21.1-24.5) 21.6 (20.3-23.1) .046
Transplant
A HLA mistmatch, mean  SD 1.29  0.60 1.31  0.62 1.28  0.60 .765
B HLA mismatch, mean  SD 1.64  0.51 1.65  0.52 1.63  0.51 .765
DR HLA mismatch, mean  SD 1.42  0.61 1.41  0.61 1.42  0.62 .867
Total HLA mismatch, mean  SD 4.35  1.04 4.37  1.11 4.33  1.01 .643
Anti-HLA antibodies, n (%) 22 (16) 9 (18) 13 (14) .545
Preformed DSA, n (%) 11 (8) 6 (12) 5 (6) .163
Pre-SPKT anti-GAD, n (%) .001
Negative 57 (41) 29 (59) 28 (31)
Positive 27 (19) 3 (6) 24 (27)
Unknown 55 (40) 17 (35) 38 (42)
Pre-SPKT anti-ICA, n (%) .470
Negative 70 (50) 28 (57) 42 (47)
Positive 15 (11) 4 (8) 11 (12)
Unknown 54 (39) 17 (35) 37 (41)
Pre-SPKT anti-IAA, n (%) .945
Negative 13 (9) 5 (10) 8 (9)
Positive 33 (24) 11 (22) 22 (24)
Unknown 93 (67) 33 (67) 60 (67)
Donor
Age, y, median (IQR) 28 (21-38) 26 (21-38) 28 (21-38) .798
Abbreviations: Anti-GAD, antieglutamic acid decarboxylase antibody; anti-IAA, antieinsulin antibody; anti-ICA, antieislet cell antibody; BMI, body mass index;
DSA, donor-specific antibody; HLA, human leukocyte antigen; IDDM, insulin-dependent diabetes mellitus; IQR, interquartile range; SPKT, simultaneous pancreas-
kidney transplant.
*N ¼ 139, after exclusion of patients without anti-GAD evaluation post-SPKT.
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annualized mean higher HbA1c (P ¼ .006) and lower C-
peptide levels (P ¼ .013) was evident in anti-GADþ group.
Regarding pre- vs post-SPKT anti-GAD assessment
(available for 84 recipients in whom pre-SPKT anti-GAD
status was known), 28 converted from negative to positive
status, 27 persisted as positive, and 59 were negative, while
3 became negative post-SPKT (P ¼ .001).
Clinical outcomes after transplantation are detailed in
Table 3. Alloimmune (ALI) events (pancreas rejection and/
or de novo DSA) occurred in 14 (10%) patients with no
differences between anti-GADþ and anti-GAD- groups
(P ¼ .223). Still regarding ALI events, no significance dif-
ference was observed in anti-GADþ and anti-GAD- pa-




(95% CI) P Valu
Anti-GAD .006
Negative 5.31 (5.18-5.44) Ref.
Positive 5.53 (5.44-5.62) 0.22 (0.06-0.38)
Abbreviations: Anti-GAD, antieglutamic acid decarboxylase antibody; CI, confidenPatient death occurred in 5 (6%) anti-GADþ and 2 (4%)
anti-GAD recipients (P > .999).
Auto-immunity: Clinical Associations and Survival
Forty-two patients showed no ALI events nor anti-GAD
antibody positivity, 14 presented with ALI events, and 83
patients reveled AI events (positive for anti-GAD and no
ALI events). At 15-year FU, pancreas survival was better in
patients with no immune events (96%) followed by ALI
(69%) and AI events (63%) (P ¼.002 for ALI and P ¼ .040
for AI events in comparison with no immune events) (Fig
1). No survival difference was found between patients with
AI and ALI events (P ¼ .192).
For the analysis of the impact of pre- vs post-SPKT





(95% CI) P Value
.013
2.91 (2.72-3.11) Ref.
2.61 (2.48-2.74) -0.30 (-0.54 to -0.06)
ce interval; HbA1c, glycated hemoglobin.










Patient and graft outcomes
Alloimmune events, n (%) 14 (10) 7 (14) 7 (8) .223
Death-censored pancreas
graft failure, n (%)
16 (12) 4 (8) 12 (13) .419
Patient deaths, n (%) 7 (5) 2 (4) 5 (6) >.999
Abbreviations: Anti-GAD, antieglutamic acid decarboxylase antibody.
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tion, 14 with AI events and a small group of 3 patients with
conversion from positive to negative anti-GAD status. Our
final sample was then classified into 3 different groups ac-
cording to pre/post SPKT anti-GAD status (negative/nega-
tive, n ¼ 27; positive/positive, n ¼ 22; negative/positive,
n ¼ 25). Figure 2 shows PG survival by anti-GAD status
pre-SPKT and post-SPKT. At 10-year FU (Fig 2), persistent
negative, persistent positive, and converted (from negative
to positive) recipients showed respectively 100%, 88%, and
63% PG survival (P ¼ .044). In pairwise comparisons, only
the difference in survival between persistent negative and
converted recipients was significant (P ¼ .038).DISCUSSION
Our study about post-SPKT PAs and their relationship
with pancreatic graft outcome has a considerable FU time
(median of 6 to 7 years) similar to other published cohorts
[13,14].
Many SPKT patients have undetectable titers of PAs;
others switch from positive to negative titers of antibodies,others maintain stable levels; while others convert from
negative to positive. Again, like other studies [5,9,10], we
report persistence, disappearance, and reappearance of
PAs. In our study, no significant association was observed
between post-SPKT ICA and IAA positivity and PG sur-
vival. Importantly, the same was not the case for anti-GAD
detection post-SPKT, which correlated with decreased PG
survival, particularly if the patient had a conversion from
negative to positive after transplant.
A recent study found that approximately 7% to 8% of all
recipients will develop IDDM recurrence, particularly those
carrying HLA DR3/DR4 genotype and sharing HLA-DR
alleles with the donor [13,15], but other studies did not
find this association significant [14]. Similar to this last
report, we were not able to discern risk factors for
anti-GAD positivity such as HLA mismatch.
Our study observed lower C-peptide levels and higher
mean of HbA1C% in the positive anti-GAD group. This is
consistent with a previous study in which a less favorable
glycemic control with a leaning to HbA1C% values higher
than 5,3% was observed in patients who developed auto-
antibody positivity [14]. The association between pancreas
autoimmunity and HbA1C% and C-peptide directs our
attention to the possible role of PAs in monitoring pancreas
AI activity. Thus, this suggests that AI should be included in
the diagnostic workup of graft failure and ideally should be
routinely assessed pretransplant and on FU.
Long-term graft loss may occur because of many factors,
including ALI responses (rejection) and recurrence of
autoimmunity. In our study, ALI events were present in 14
patients, and AI events (anti-GADþ but no ALI events)
were found in more than 50% of our cohort (n ¼ 83 pa-
tients). Although our study showed worse PG survival forFig 1. Pancreas graft survival by
alloimmune and autoimmune factors.
Fig 2. Pancreas graft survival by
antieglutamic acid decarboxylase
status pree and postesimultaneous
pancreas-kidney transplantation.
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cant differences between them was found. It seems that,
despite advances in immunosuppression that prevent
rejection, AI and ALI events continue to have a negative
impact on PG survival on the long-term.
A key finding, which is confirmed in our study and that
extends earlier studies is that autoantibody conversion, as
opposed to persistence or negativity, is associated with a
high risk of developing IDDM [5,10,15]. Although associ-
ation between PAs and beta cell destruction seems to be
more consistent with anti-GAD antibody in the literature
[7], this topic continues to be controversial. In fact, Assa-
lino et al [16] reported a case of confirmed autoimmunity
recurrence in which a patient's PAs (GAD-65, IA-2) never
converted to positive levels. The real significance and
impact of the antibodies on long-term PG survival are still
unclear. Our study appears to support findings of other
previous published works [7,10,17], in which an association
occurs between the recurrence of PAs and poor pancreas
survival. At 10-year FU, converted (from negative to posi-
tive) anti-GAD recipients showed a 63% survival compared
with those with persistent negative anti-GAD, who
revealed a 100% survival rate. Persistence of anti-GAD
positivity did not confer poorer graft survival when
comparing with no anti-GAD status pre- and
post-transplant.
We recognize that this study has some limitations. First,
the high number of missing values of pancreatic anti-
bodies before SPKT hampers a stronger observation of
the effect on PG survival of persistence vs conversion anti-
GAD status. Second, no information about compliancewith immunosuppression was available. Last, the absence
of histologic confirmation of AI-mediated PG injury
phenotype in association with autoantibodies (re-)emer-
gence prevents us from making any causation assumption.
It is believed that pancreatic lesion due to the AI process
may be the consequence of the action of complement-
activating antibodies targeted at the epitopes of the beta
cells or also the result of the lytic action of cytotoxic T
lymphocytes or even the sum of the immunologic response
components [18]. It is also known that pathogenic auto
reactive CD4 T-cells are associated to B-cell destruction
and IDDM recurrence [19]. Further studies will help
determine whether assessment of auto-reactive T-cells im-
proves autoantibody prediction. Unfortunately, so far, no
current therapeutic regimen has controlled the progression
of islet autoimmunity, even when additional immunosup-
pression was added to the ongoing chronic regimens [15].
The development of new treatment regimens aiming to
control autoimmunity is needed, as this may not be effec-
tively suppressed by conventional immunosuppression.
Nevertheless, only new and efficacious therapeutic strate-
gies would clearly change the adverse prognosis associated
with autoimmunity recurrence.CONCLUSION
In conclusion, we consider that our results demonstrate a
strong association between post-SPKT anti-GAD antibody
detection, PG worse function, and lower survival in SPKT,
with this latter effect being particularly noticeable in cases
of de novo emergence of this autoantibody after SPKT.
AUTOANTIBODIES IN PANCREAS GRAFT SURVIVAL 1375Hence, longitudinal anti-GAD antibody pattern may
improve the clinical management of SPKT recipients,
signaling those cases with a higher risk of AI-driven PG lost.
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